Shuchi Nahar's Weekend Blog!

CAPEX Acceleration in Indian Chemical Companies -  USD 300 bn  domestic market by 2025 Twitter Handle: @shuchi_nahar India’s chemical industry was estimated to be worth USD 178 billion in FY 2019-20 and has a significant potential to reach USD 300 billion by FY 2024-25. In terms of demand, the industry has grown at approximately 1.3 times the country’s average GDP growth in the last five years and shows a strong linkage with its GDP. Indian specialty chemical sector has grown at 12%+ in the last five years and is well poised to expand its global market share to 7-8% from 4% in the coming years. The structural drivers are in place like global best practice manufacturing standard and R&D capability along with government impetus of make in India policy with pro-growth policies will act as a further catalyst for growth. Further, a global MNC looking at China Plus one strategy will help Indian incumbents to gain market share. In the short to medium term, supply disruptions emerging

Recent disruption in China - Impact on Indian Chemical Companies Twitter Handle: @shuchi_nahar Specialty Chemical Article: https://myweekendspot.blogspot.com/2021/07/speciality-chemicals-market-size-demand.html Government scheme to boost: https://myweekendspot.blogspot.com/2021/07/government-initiatives-to-boost-growth.html Indian specialty chemicals companies are poised to ride tailwinds from macro drivers including ‘China+1’, import-substitution, growing costs within China (capital, operational, compliances), and currency benefits.  Recent disruptions in China will cause medium-term challenges for downstream producers while benefiting base chemical suppliers. More importantly, these frequent supply disruptions in China further strengthen the case for quality Indian players in the chemical domain. Growing import substitution by local industry makes a case for strengthening volume growth for base chemical/intermediate suppliers.  Recent disruptions in China (electricity shortages,

Syngene International Ltd. FY2020-21 Annual Report Key Takeaways  In continuation of my previous blog here is the updated version l ink to Initial Blog -  https://myweekendspot.blogspot.com/2020/10/syngene-next-giant-player-for-cdmo.html Company Overview Incorporated in 1994 as a subsidiary of Biocon, Syngene International (SIL) is a leading contract research organization (CRO), which supports R&D programs of global innovative companies.   SIL offers outsourced services to support discovery and development for organizations across industrial sectors like pharmaceuticals, biopharmaceuticals, nutraceuticals, animal health, agrochemicals, etc. It currently caters to 400+ global players including Bristol-Myers Squibb (BMS), Abbott, Baxter, and Amgen, among others. SIL derives 95% of its revenues from exports.   Syngene continued to build on its integrated drug discovery and development portfolio during the year, including a five-year collaboration with 3DC, the drug discovery